US Patent 12,589,086 for Elafibranor in UDCA-Intolerant Primary Biliary Cholangitis: Claim Scope, Patent Landscape, and Expiration/Challenge Risk
US Patent 12,589,086 is directed to a method of treating primary biliary cholangitis (PBC) using elafibranor in patients who are intolerant to ursodeoxycholic acid (UDCA). The core claim set is method-of-treatment, with scope anchored on (i) the specific active ingredient and composition identity (elafibranor or salts), (ii) the patient eligibility requirement (UDCA intolerance, including specified contraindications and adverse events), and (iii) optional dosage-form and dosing parameters.
The claims are narrowest where the patent narrows eligibility to particular UDCA contraindications/adverse events, and widest where it only requires “intolerant to UDCA” without restricting which intolerance phenotype. The practical enforceability hinge is whether the accused use can be characterized as “UDCA-intolerant,” not merely “PBC treated.”
What is the exact claim scope of US Patent 12,589,086 for elafibranor in UDCA-intolerant PBC?
Broadest independent concept (Claim 1)
Claim 1 requires all elements:
- A method of treating PBC
- Administering a pharmaceutical composition comprising
- Elafibranor (2-(2,6-dimethyl-4-{3-[4-(methylsulfanyl)phenyl]-3-oxopropen-1-yl}phenoxy)-2-methylpropanoic acid) or a pharmaceutically acceptable salt
- To a patient who suffers from PBC and is intolerant to UDCA
Key enforceability boundary
The patent is not for elafibranor broadly in PBC. It is for elafibranor in UDCA-intolerant PBC.
Meaning of “intolerant to UDCA” embedded in claim set
Because dependent claims identify specific contraindications and specific adverse-event categories, the specification-free claim logic strongly suggests the patentee intended a clinical framing similar to UDCA failure/intolerance cohorts used in PBC treatment guidance.
How do dependent claims narrow patient phenotype and clinical triggers?
Claim 2 (conditional widen/clarify within “intolerance”)
Patient has:
- a contraindication to UDCA, or
- inability to be compliant due to an adverse event or condition
This claim expands beyond pure contraindication into noncompliance due to intolerance events, which is often easier to argue in real-world prescribing than a formal contraindication label.
Claim 3 (list of specific UDCA contraindications)
Constrains claim 2 to patients including:
- pregnant women
- complete biliary obstruction of extrahepatic origin
- widespread intrahepatic obstruction
- patients with calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones, plus malfunctioning gallbladder
- acute inflammation of gallbladder or biliary tract
- frequent biliary colic
This is where infringement arguments become fact-intensive. If an accused patient lacks these listed contraindications and the court treats the list as limiting, Claim 3 may be harder to reach.
Claim 4 (adverse event/condition list)
Defines adverse-event categories including:
- leucopenia
- ulcerates
- immune suppression with consequent fever
- incoercible/unexplained diarrhea
- infections/URI-like: pneumonia, pharyngitis, otitis media, bronchopneumonia, bronchitis, oral moniliasis
- abscess formations
- dysuria or recurrent watery diarrhea
- GI: stomach burns
- immune/vasculitic: leukocytoclastic vasculitis
- skin: skin rash
- hematologic: thrombocytopenia
- pulmonary: recurrent wheezy chest, cough, interstitial lung disease
- hepatic complications: vanishing bile duct syndrome, pruritus, cholangitis, ascites, increasing cholestasis, portal hypertension, liver cell failure
- neuro/metabolic: convulsions, diabetes
- general symptoms: nausea, vomiting, sleep disturbance
This is the second major narrowing point. Depending on claim construction, Claim 4 either:
- limits infringement to the enumerated intolerance events, or
- treats the list as examples with broader read-through (but the presence of an express “adverse event or condition is [enumerated list]” typically invites limiting interpretation).
How do dosage-form and dosing claims expand practical coverage?
Claim 5 (dosage forms)
Includes many dosage forms: tablet, injectable suspension, gel, oil, pill, suppository, powder, gel cap, capsule, aerosol, and prolonged/slow release dosage forms.
This claim is broad on delivery form but still anchored to “administering a pharmaceutical composition comprising elafibranor… for treating PBC UDCA-intolerant.”
Claim 6 (frequency)
Oral administration once a day.
This restricts use if the accused regimen is multiple daily dosing.
Claim 7-9 (dose ranges and tablet strength)
- Claim 7: dose range 10 mg to 200 mg per administration
- Claim 8: specific range 80 mg to 120 mg per administration
- Claim 9: tablet comprising 80 mg elafibranor
This cluster creates a ladder:
- Claim 7 is relatively broad (covers many dose-selection strategies)
- Claim 8 is narrower
- Claim 9 is narrowest (80 mg tablet), important for “strength-specific” marketing and generic design-around.
Bottom-line scope map
| Claim |
What must be proven for infringement |
Main narrowing lever |
Practical “design-around” surface |
| 1 |
PBC + UDCA intolerance + elafibranor composition |
“UDCA intolerance” definition and proof |
Change indication/eligibility framing, challenge “intolerant” evidence |
| 2 |
Adds contraindication or noncompliance due to adverse event |
clinical labeling and event causality |
Reduce reliance on intolerance narrative; argue different cause |
| 3 |
Adds pregnancy/obstruction/stone/gallbladder inflammation criteria |
listed contraindication facts |
Use patients outside listed categories |
| 4 |
Adds specific adverse event categories |
strict event-by-event fit |
Argue different adverse-event profile or non-UDCA causation |
| 5 |
Defines acceptable dosage forms |
mostly irrelevant if oral dominates |
Use only a dosage form outside list (unlikely) |
| 6 |
Oral once daily |
regimen timing |
Different schedule than once daily |
| 7 |
10-200 mg dosing |
dose selection |
Use outside range |
| 8 |
80-120 mg dosing |
dose selection |
Use outside 80-120 mg |
| 9 |
80 mg tablet |
strength specificity |
Use different strength or not tablet |
How strong is the patent estate for this specific UDCA-intolerant PBC method?
Strength driver: eligibility-limited method claim
A method claim that requires a specific patient subgroup tends to be strong against broad generic substitution, because the alleged infringing act must match the clinical eligibility. It also means enforcement depends on whether a physician’s prescribing and a patient’s history can be tied to “UDCA intolerance” as construed.
Weakness driver: dependence on enumerated contraindications/adverse events
Claims 3 and 4 are both detailed. Courts can construe lists as limiting. If so, infringement of dependent claims becomes harder. Claim 1 and Claim 2 should be easier to reach because they only require “intolerant” or “contraindication/noncompliance due to adverse event,” not the particular list items.
Weakness driver: regimen parameters create easy “carve-outs”
Claims 6-9 add constraints (once daily, dose range, 80 mg tablet). If an accused regimen departs from those constraints, those dependent claims may be non-infringing while Claim 1 and Claim 2 remain asserted targets.
What patents likely cover the elafibranor substance and earlier PBC use, and how do they intersect with US 12,589,086?
Based on the claim drafting style, US 12,589,086 sits in a typical structure within a compound’s patent estate:
- Compound / composition patents covering elafibranor itself (and salts)
- Pharmaceutical formulation patents
- Method-of-use patents, including disease areas and patient subgroups
This particular patent is not a “new chemical entity” claim; it is a use patent focused on PBC + UDCA intolerance. That typically means it relies on the compound being already protected or commercially available under earlier approvals, with the use patent extending exclusivity and litigation leverage.
Estate intersection risk for challengers
If earlier compound patents remain in force, a generic entry could be blocked irrespective of use-subgroup design. If not, then the main enforcement lever is whether a challenger’s product labeling and prescribing can avoid the “UDCA-intolerant” method.
When does US Patent 12,589,086 lose exclusivity and what are the key expiration dates to model?
US 12,589,086 is a granted patent, but the prompt does not provide the patent’s filing date, priority date, or maintenance fee history, so specific expiration dates cannot be computed here from claim text alone.
No complete and accurate expiration timeline can be produced without the patent bibliographic data (filing/priority/term adjustments).
What generic entry risks exist for elafibranor UDCA-intolerant PBC under an FDA Paragraph IV strategy?
The core Paragraph IV question
A Paragraph IV filing would typically certify that the listed patents are invalid, unenforceable, or not infringed by the proposed generic product.
Because this patent is a method-of-treatment claim with a patient subgroup limitation:
- A generic could attempt to argue noninfringement on the basis that the proposed label does not instruct UDCA-intolerant use, or that it does not meet the method steps as construed (particularly the “intolerant” element).
- In practice, courts often focus on whether the label induces the claimed method.
Label and inducement exposure
If the generic’s label includes use for PBC patients intolerant to UDCA, inducement risk increases. If the label is narrowed to UDCA-responders or UDCA-naïve populations, the label may attempt to avoid the claimed subgroup.
What is the Orange Book status of US 12,589,086 and which FDA regulatory events control enforcement?
No Orange Book listing data is provided in the prompt, so Orange Book status, listed drug associations, and exclusivity linkages cannot be accurately stated.
Method-of-use patents are often listed in the Orange Book, but the mapping to this exact patent requires the FDA listed drug and patent listing record.
How does US 12,589,086 compare with other PBC treatment patent strategies (UDCA failures vs intolerant subgroups)?
This patent uses a particular clinical discriminator: UDCA intolerance. Other PBC patents commonly target:
- inadequate response to UDCA
- biomarker-defined nonresponse
- refractory PBC despite UDCA
- combinations or add-on regimens
If those exist in the estate, they may overlap but also create litigation complexity: different claims can be infringed by different clinical cohorts.
Litigation geometry
- “Inadequate response” cohort patents tend to cover patients who tolerate UDCA but do not respond.
- “Intolerant to UDCA” cohort patents cover patients who cannot stay on UDCA.
This creates different patient facts and different label formulations.
What patent litigation affects US 12,589,086 and what settlement patterns should be expected?
No litigation docket, parties, or settlement information is provided in the prompt, so infringement/validity proceedings cannot be tied to this patent here.
Key Takeaways
- US 12,589,086 claims a UDCA-intolerant PBC method using elafibranor (or salts).
- Claim 1 is the main enforceable anchor: PBC + elafibranor administration + UDCA intolerance.
- Claims 3 and 4 significantly narrow infringement by enumerated UDCA contraindications and specific UDCA adverse-event categories, which can increase fact burden for plaintiffs.
- Claims 6-9 add regimen constraints (oral once daily, dose ranges, and a specific 80 mg tablet strength), which create potential noninfringement routes if an accused regimen differs.
- Expiration, Orange Book listing, Paragraph IV/label strategy, and litigation effects cannot be precisely determined from the claim text alone.
FAQs
- Does US 12,589,086 require a formal UDCA “contraindication” or can it cover intolerance due to adverse events?
- Are the enumerated contraindications in Claim 3 treated as limiting categories for infringement analysis?
- Can a generic avoid infringement by changing dose frequency or dose strength outside the 80-120 mg and 80 mg tablet ranges?
- How does label wording about “UDCA intolerance” versus “inadequate response to UDCA” affect method-of-use infringement risk?
- If a patient previously took UDCA but discontinued due to GI or hepatic symptoms, which dependent claim category is most likely implicated?
References (APA)
- [No citable bibliographic sources were provided in the prompt for US 12,589,086 prosecution, priority, bibliographic data, Orange Book listing, or litigation records.]
